This story is an example of what’s often missing in medical research stories in a business section. The story is about a new cardiovascular stent that may be available if it receives approval from the Food and Drug Administration. But the story does not provide much insight about the actual utility of implanting stents. The story quoted an investigator on the project as saying that there was a lower heart-attack rate in those patients receiving this new stent. However – the published study indicated that while there were fewer heart attacks, this difference was not statistically significant. Beyond this, it is a comparison of heart attack rates in individuals who received stents and does include any indication of how this rate compares to that seen in people receiving optimal medical therapy but who don’t get a stent.
The story fails to deliver any independent perspective – only letting us hear from a company spokesman and one study investigator.
Not everyone who reads medical research stories in a business section is interested primarily as a shareholder. Some people want more context, more on the quality of the evidence, more on the size of the potential benefits and harms, and more on what this thing is likely to cost them. This story – which reported more on the competition among or revenues for device manufacturers – didn’t help those readers. And when you think of it, why wouldn’t shareholders want that missing information as well?
The story did not project any cost of this new stent; it did provide estimates for the amount of sales revenue generated by those drug-eluting stents that are currently available to consumers. (The story also did not provide information about how much these stents cost consumers either.) There was no discussion of associated costs for the medications that need to accompany the use of these drug eluting stents.
The story did not adequately explain the intended appropriate use for this new stent. The story indicated that the new stent decreased the need for repeat treatment in the target vessel and that the new stent decreased the occurrence rate for heart attacks. There was no comparison of this stent with no stent at all. In addition – as the information provided either came from the oral presentation at a conference or from the company news release – and has not been peer reviewed – the story should have been explicit about the source of the limited information it did present.
The story provided quantitative data indicating that the rate at which blood clot formation occurred after implanting the new stent was comparable to the rate with one of the currently available drug-eluting stents. However there was no information about how the harms with this new stent compared with bare metal stents or no stent at all.
The story included some quantitative data from the research paper published in April 2008; it mentioned some of the research findings that were presented at a recent meeting. It did not include the specific data from this meeting which is appropriate given their preliminary nature. That said, the story is really about claims that this new drug-eluting stent is better than the currently available drug-eluting stents and since the data backing that claim has not yet been reviewed by objective experts in the field, the story should have stated this explicitly.
The story engaged in subtle disease mongering because in its discussion of the use for this new product to treat ‘blocked blood vessels’ it failed to acknowlege that in fact, national guidelines don’t recommend the use of stents to treat all blocked coronary arteries, only those through which flow is occluded 70% or more.
The story would have benefited greatly by including comment(s) from someone other than a company spokesperson or someone involved in the study. This could have provided readers with some insight about what this new product might add to the field.
The story did not even provide a clear picture of what would be involved in treatment using the medical device highlighted, let alone outline the other options available for those with cardiovascular disease.
It’s clear from the story that the stent in question is not yet approved by the FDA.
The story was about one more drug-eluting stent that may come on the market but it was unclear about how this stent differs from those currently on the market.
We can’t be sure if the story relied solely or largely on a news release, but the quantitative information about the benefit of this product appears to rely on the company news release. If not, the story should have explained where it came from. We do know the story only included comments from the company and from someone involved in the study – no independent perspectives.
Systematic, Criteria-Driven
Monday at #ADA2021, an infectious disease epidemiologist, a journalist, and a researcher shared perspectives on communication of risk in the era of COVID-19: http://ow.ly/ROfR30rMeE7 @AstleyCM @garyschwitzer @berthahidalgo @ADA_DiabetesPro
Shoutouts to @susan_bewley @drkevinknopf @MichaelBaum11 in this call for more than fawning coverage from press releases for these kinds of stories.
Also, linked history inside goes back 5 years just on Grail apparently trying to become Holy Grail. https://twitter.com/garyschwitzer/status/1408849696416841731
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like